Updated: January 12, 2026
How Does Padcev Work? Mechanism of Action Explained in Plain English
Author
Peter Daggett
ChatGPT
Claude
Gemini
Overview
Padcev is an antibody-drug conjugate that targets Nectin-4 on cancer cells, then releases MMAE to kill them. Here's a plain-English explanation of how it works.
Is Padcev in stock near you?
Medfinder checks real pharmacy inventory — start a search and we'll find Padcev near you.
Padcev (enfortumab vedotin-ejfv) represents one of the most innovative advances in cancer treatment in recent decades. It belongs to a new class of drugs called antibody-drug conjugates (ADCs) — a "smart bomb" approach to cancer therapy that delivers a toxic payload directly to cancer cells while largely sparing healthy tissue.
Understanding how Padcev works can help patients and caregivers feel more informed and empowered during treatment. Let's break it down step by step.
What Is an Antibody-Drug Conjugate (ADC)?
Before understanding Padcev specifically, it helps to understand ADCs in general. An ADC consists of three parts:
A targeting antibody: A protein designed to recognize and bind to a specific target (antigen) found on cancer cell surfaces
A linker: A chemical bridge connecting the antibody to the drug payload. The linker is designed to remain intact in the bloodstream but break apart once inside a cancer cell
A cytotoxic payload: A powerful cell-killing drug attached to the antibody via the linker, which is released inside the cancer cell to destroy it
Think of an ADC like a guided missile: the antibody is the targeting system that homes in on cancer, the linker is the safety mechanism, and the payload is the explosive charge.
Check live stock now.
What Target Does Padcev Aim At?
Padcev is specifically designed to target a protein called Nectin-4 (also known as PVRL4). Nectin-4 is a cell adhesion molecule that is expressed at high levels on the surface of urothelial cancer cells — bladder, ureter, renal pelvis, and urethra — making it an ideal target for this cancer type.
Nectin-4 is present at lower levels in some normal tissues, but its overexpression in urothelial cancer cells means that Padcev's antibody preferentially binds to cancer cells, delivering the toxic payload where it's most needed.
The Three Parts of Padcev
Padcev is comprised of three distinct components:
The antibody (AGS-22C3): A fully human IgG1 kappa monoclonal antibody that binds specifically to Nectin-4
The linker (SGD-1006): A protease-cleavable maleimidocaproyl valine-citrulline (mc-vc) linker that keeps the ADC intact in circulation but releases MMAE when cleaved by enzymes inside the cancer cell
The payload (MMAE): Monomethyl auristatin E — a potent microtubule-disrupting agent. Approximately 3.8 MMAE molecules are attached to each antibody molecule (drug-to-antibody ratio of ~3.8:1)
Step-by-Step: How Padcev Kills Cancer Cells
Binding: After IV infusion, Padcev circulates through the bloodstream. When it encounters a cell displaying Nectin-4 on its surface, the antibody component locks on.
Internalization: The cancer cell "swallows" the Padcev-Nectin-4 complex, pulling it inside the cell through a process called receptor-mediated endocytosis.
Linker cleavage: Inside the cell, proteolytic enzymes in lysosomes cleave the mc-vc linker, releasing free MMAE into the cell's cytoplasm.
Microtubule disruption: MMAE binds to tubulin — the protein that forms the microtubule network the cell needs to divide. By disrupting microtubule polymerization, MMAE prevents the cell from completing cell division.
Cell death: Unable to divide, the cancer cell undergoes apoptosis (programmed cell death). MMAE can also diffuse into neighboring cells ("bystander effect"), potentially killing Nectin-4-negative cells nearby.
Why Does Padcev Also Pair So Well With Pembrolizumab?
Padcev's combination with pembrolizumab (Keytruda) — a PD-1 checkpoint inhibitor — is more than additive. When cancer cells die from MMAE-induced damage, they release cellular debris and tumor antigens that can help the immune system recognize and attack remaining cancer cells. This is called immunogenic cell death. Pembrolizumab amplifies this immune response by blocking the PD-1 checkpoint that cancer cells use to hide from immune attack. Together, the two drugs create a powerful one-two punch that neither drug achieves as well alone.
Why Does Understanding the Mechanism Matter for Patients?
Understanding how Padcev works helps explain its side effect profile. Since MMAE's main job is to disrupt cells that divide, any rapidly dividing normal cells — like those in skin, nerves, and hair follicles — can be affected, leading to skin reactions, peripheral neuropathy, and hair loss. Knowing this helps you understand why your care team monitors you so closely and why reporting symptoms quickly matters.
Read more about managing Padcev side effects in: Padcev Side Effects: What to Expect and When to Call Your Doctor.
If you're looking for an infusion center near you that can administer Padcev, medfinder can help you find one quickly.
Frequently Asked Questions
Yes. Padcev is a targeted therapy in the form of an antibody-drug conjugate (ADC). It targets Nectin-4, a protein overexpressed on urothelial cancer cells. Unlike traditional chemotherapy, which affects all dividing cells throughout the body, Padcev's antibody guides the cytotoxic payload (MMAE) to Nectin-4-expressing cancer cells.
MMAE (monomethyl auristatin E) is the cytotoxic payload attached to the antibody in Padcev. It is a potent microtubule-disrupting agent — it prevents cancer cells from dividing by blocking the formation of the spindle apparatus needed for cell division, causing the cell to die. MMAE is too toxic to use on its own, which is why it's attached to a targeting antibody via a linker in the ADC format.
No. Unlike some targeted therapies (like erdafitinib, which requires FGFR mutation testing), Padcev does not require prior biomarker testing for Nectin-4 expression. Clinical studies have shown it is effective across a broad range of urothelial cancer patients regardless of Nectin-4 expression level, since most urothelial cancer cells express this protein at high levels.
Traditional chemotherapy attacks all rapidly dividing cells, which is why it causes widespread side effects like hair loss, nausea, and bone marrow suppression. Padcev's antibody component targets Nectin-4 specifically on cancer cells, so the MMAE payload is delivered more selectively. However, Padcev still causes some chemotherapy-like side effects because MMAE can affect normal tissues and some MMAE leaks into circulation ('bystander' effect).
Medfinder Editorial Standards
Medfinder's mission is to ensure every patient gets access to the medications they need. We are committed to providing trustworthy, evidence-based information to help you make informed health decisions.
Read our editorial standardsPatients searching for Padcev also looked for:
More about Padcev
Why Is Padcev So Hard to Access? [Explained for 2026]
How to Find Padcev in Stock Near You (Tools + Tips)
Alternatives to Padcev If You Can't Fill Your Prescription
Padcev Access Update: What Patients Need to Know in 2026
Padcev Access Challenges: What Providers and Prescribers Need to Know in 2026
How to Help Your Patients Find Padcev in Stock: A Provider's Guide
39,483 have already found their meds with Medfinder.
Start your search today.
Your information is private and never shared.